{"filing":{"accession_number":"0001294133-26-000025","cik":"0001294133","ticker":"INGN","company_name":"Inogen Inc","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ingn-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1294133/000129413326000025/ingn-20260701.htm"},"events":[{"id":15484,"run_id":13812,"accession_number":"0001294133-26-000025","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Inogen appointed Andrew Reding as Executive Vice President and Chief Operating Officer, a newly created C-suite role effective July 6, 2026. The appointment includes compensatory arrangements comprising a base salary of $500,000, a 70% bonus target, a $100,000 sign-on bonus, and 130,000 RSUs vesting over three years, approved under Nasdaq Listing Rule 5635(c)(4).","company_name":"Inogen Inc","ticker":"INGN","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13276,"accession_number":"0001294133-26-000025","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Andrew Reding as Executive Vice President and Chief Operating Officer of Inogen, effective July 6, 2026. This is a newly created C-suite role with significant operational responsibilities. While the disclosure also includes compensatory arrangements (base salary of $500,000, 70% bonus target, $100,000 sign-on bonus, and 130,000 RSUs), the principal disclosed action is the appointment itself to a material executive position, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:12:55.672974+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13277,"accession_number":"0001294133-26-000025","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Andy Reding as Chief Operating Officer, a newly created role effective July 6, 2026. The press release emphasizes his 30+ years of leadership experience in medical technology and his responsibility for \"driving revenue and operational performance\" and translating strategy into outcomes. The appointment includes a material inducement equity award of 130,000 RSUs vesting over three years, approved under Nasdaq Listing Rule 5635(c)(4). This is a clear executive appointment of a named officer to a senior leadership position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:12:55.672974+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13276,"accession_number":"0001294133-26-000025","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Andrew Reding as Executive Vice President and Chief Operating Officer of Inogen, effective July 6, 2026. This is a newly created C-suite role with significant operational responsibilities. While the disclosure also includes compensatory arrangements (base salary of $500,000, 70% bonus target, $100,000 sign-on bonus, and 130,000 RSUs), the principal disclosed action is the appointment itself to a material executive position, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:12:55.672974+00:00","company_name":"Inogen Inc","ticker":"INGN","filing_date":"2026-07-01"},{"id":13277,"accession_number":"0001294133-26-000025","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Andy Reding as Chief Operating Officer, a newly created role effective July 6, 2026. The press release emphasizes his 30+ years of leadership experience in medical technology and his responsibility for \"driving revenue and operational performance\" and translating strategy into outcomes. The appointment includes a material inducement equity award of 130,000 RSUs vesting over three years, approved under Nasdaq Listing Rule 5635(c)(4). This is a clear executive appointment of a named officer to a senior leadership position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:12:55.672974+00:00","company_name":"Inogen Inc","ticker":"INGN","filing_date":"2026-07-01"}]}